


PRD 2023USPCT

Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

Listing of Claims

1. (Original) A compound having the formula



the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

n represents an integer being 0, 1 or 2;


m represents an integer being 0 or 1;

*R*¹ and *R*² each independently represents hydrogen, C₁₋₄alkyl, NR⁹R¹⁰, C₁₋₄alkyloxy, Het³-O-C₁₋₄alkyl; or

*R*¹ and *R*² taken together with the carbon atom with which they are attached form a carbonyl, or a C₃₋₆cycloalkyl; and where *n* is 2, either *R*¹ or *R*² may be absent to form an unsaturated bond;

*R*³ represents hydrogen, Ar¹, C₁₋₈alkyl, C₆₋₁₂cycloalkyl or a monovalent radical having one of the following formulae

PRD 2023USPCT



wherein said Ar^1 , C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two or three substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, phenyl, halo, oxo, carbonyl, 1,3-dioxolyl or hydroxy;

R^4 represents hydrogen, C_{1-4} alkyl, or C_{2-4} alkenyl;

Q represents C_{3-8} cycloalkyl, Het^1 or Ar^2 , wherein said C_{3-8} cycloalkyl, Het^1 or Ar^2 are optionally substituted with one or where possible more substituents selected from halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, nitro, Het^4 , phenyl, phenyloxy, C_{1-4} alkyl-oxycarbonyl, hydroxycarbonyl, NR^5R^6 , C_{1-4} alkyloxy substituted with one or where possible two or three substituents each independently selected from C_{1-4} alkyl, hydroxycarbonyl, Het^2 , C_{1-4} alkyl or NR^7R^8 ,

C_{2-4} alkenyl substituted with one substituent selected from phenyl- C_{1-4} alkyl-oxycarbonyl, C_{1-4} alkyloxycarbonyl, hydroxycarbonyl or Het^5 -carbonyl, and

C_{1-4} alkyl substituted with one or where possible two or three substituents independently selected from halo, dimethylamine, trimethylamine, amine, cyano, Het^6 , Het^7 -carbonyl, C_{1-4} alkyloxycarbonyl or hydroxycarbonyl;

R^5 and R^6 are each independently selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkyloxy- C_{1-4} alkyl, C_{1-4} alkyloxycarbonyl, C_{1-4} alkylcarbonyl, C_{1-4} alkylcarbonyl substituted with one or where possible two or three substituents each independently selected from halo,

PRD 2023USPCT

- C₁₋₄alkyl, and C₁₋₄alkyloxy or R⁵ and R⁶ each independently represent C₁₋₄alkyl substituted with phenyl;
- R⁷ and R⁸ are each independently selected from hydrogen or C₁₋₄alkyl;
- R⁹ and R¹⁰ are each independently selected from hydrogen, C₁₋₄alkyl or C₁₋₄alkyloxy;
- L represents C₁₋₄alkyl optionally substituted with one or where possible more substituents selected from C₁₋₄alkyl or phenyl;
- Het¹ represents a heterocycle selected from pyridinyl, piperidinyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, furanyl, benzofuranyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, benzothiophenyl, thiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;
- Het² represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl, said Het² optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, C₁₋₄alkyl or C₁₋₄alkyloxy;
- Het³ represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;
- Het⁴ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl, triazolyl, tetrazolyl or morpholinyl, said Het⁴ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy;
- Het⁵ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁵ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy; in particular piperazinyl or morpholinyl;
- Het⁶ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁶ optionally being

PRD 2023USPCT


substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy;

Het⁷ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁷ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy; in particular selected piperazinyl or morpholinyl;

Ar¹ represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, biphenyl, indenyl, 2,3-dihydroindenyl, fluorenyl, 5,6,7,8-tetrahydronaphthyl or naphthyl

Ar² represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, biphenyl, benzocyclobutenyl, benzocycloheptanyl, benzosuberonyl, indenyl, 2,3-dihydroindenyl, fluorenyl, 1,2-dihydronaphthyl, 5,6,7,8-tetrahydronaphthyl or naphthyl.

2. (Original) A compound having the formula



the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein


n represents an integer being 0, 1 or 2;

m represents an integer being 0 or 1;

R¹ and R² each independently represents hydrogen, C₁₋₄alkyl, NR⁹R¹⁰, C₁₋₄alkyloxy, Het³-O-C₁₋₄alkyl; or

R¹ and R² taken together with the carbon atom with which they are attached form a carbonyl, or a C₃₋₆cycloalkyl; and where *n* is 2, either R¹ or R² may be absent to form an unsaturated bond;

R³ represents hydrogen, Ar¹, C₁₋₈alkyl, C₆₋₁₂cycloalkyl or a monovalent radical having one of the following formulae



wherein said Ar¹, C₆₋₁₂cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two or three substituents selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyloxy, phenyl, halo, oxo, carbonyl, 1,3-dioxolyl or hydroxy;

R⁴ represents hydrogen or C₁₋₄alkyl;

Q represents C₃₋₈cycloalkyl, Het¹ or Ar², wherein said C₃₋₈cycloalkyl, Het¹ or Ar² are optionally substituted with one or where possible more substituents selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, nitro, Het⁴, phenyl, phenyloxy, C₁₋₄alkyloxycarbonyl, hydroxycarbonyl, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het² and NR⁷R⁸, and

C₁₋₄alkyl substituted with one or where possible two or three halo substituents;

R⁵ and R⁶ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyl substituted with one or where possible two or three substituents each independently selected from halo, C₁₋₄alkyl, and C₁₋₄alkyloxy or R⁵ and R⁶ each independently represent C₁₋₄alkyl substituted with phenyl;

R⁷ and R⁸ are each independently selected from hydrogen or C₁₋₄alkyl;

R^9 and R^{10} are each independently selected from hydrogen, C_{1-4} alkyl or C_{1-4} alkyloxycarbonyl; PRD 2023USPCT

L represents C_{1-4} alkyl optionally substituted with one or where possible more substituents selected from C_{1-4} alkyl or phenyl;

Het¹ represents a heterocycle selected from pyridinyl, piperidinyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, furanyl, benzofuranyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, benzothiophenyl, thiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, or 1,3-benzodioxolyl.;

Het² represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl;

Het³ represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;

Het⁴ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁴ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4} alkyl or C_{1-4} alkyloxy;

Ar¹ represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, biphenyl, indenyl, 2,3-dihydroindenyl, fluorenyl, 5,6,7,8-tetrahydronaphthyl or naphthyl

Ar² represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, biphenyl, indenyl, 2,3-dihydroindenyl, fluorenyl, 5,6,7,8-tetrahydronaphthyl or naphthyl.


3. (Previously Presented) A compound according to claim 1 wherein;

n represents an integer being 1 or 2 provided that when n represents 2, Q represents Het¹ or Ar², wherein said Het¹ or Ar² are optionally substituted with one or where possible more substituents selected from halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, nitro, Het⁴, phenyl, phenyloxy, hydroxycarbonyl, NR^5R^6 , C_{1-4} alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het² and NR^7R^8 , and

PRD 2023USPCT

C₁₋₄alkyl substituted with one or where possible two or three halo substituents

4. (Previously Presented) A compound according to claim 1 wherein;
 R¹ and R² each independently represents hydrogen C₁₋₄alkyl, NR⁹R¹⁰; or
 R¹ and R² taken together with the carbon atom with which they are attached form a
 C₃₋₆cycloalkyl; and where n is 2, either R¹ or R² may be absent to form an
 unsaturated bond;
 R³ represents a C₆₋₁₂cycloalkyl or a monovalent radical having one of the following
 formulae



- wherein said C₆₋₁₂cycloalkyl or monovalent radical may optionally be substituted
 with one, or where possible two, three or more substituents selected from the group
 consisting of C₁₋₄alkyl, C₁₋₄alkyloxy, halo, carbonyl, hydroxy, or 1,3-dioxolyl;
 Q represents Het¹ or Ar² wherein said Het¹ or Ar² are optionally substituted with one or
 where possible two or more substituents selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy,
 hydroxy, C₁₋₄alkyloxycarbonyl, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where
 possible two or three substituents each independently selected from
 hydroxycarbonyl, Het² and NR⁷R⁸, and C₁₋₄alkyl substituted with one or where
 possible two or three substituents each independently selected from halo,
 dimethylamine, amine, cyano, Het⁶, Het⁷-carbonyl or hydroxycarbonyl;
 R⁵ and R⁶ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkylcarbonyl, C₁₋₄
 alkylcarbonyl substituted with one or where possible two or three halo substituents.

PRD 2023USPCT

R^9 and R^{10} are each independently selected from hydrogen or C_{1-4} alkyl;

L represents a C_{1-4} alkyl, preferably methyl;

Het¹ represents a heterocycle selected from pyridinyl, pyrimidinyl, thiophenyl, benzothiophenyl, quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzo-pyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;

Het² represents a monocyclic heterocycle selected from piperidinyl, piperazinyl, pyridinyl, pyrrolidinyl or morpholinyl, said Het² optionally being substituted with one or where possible two or more C_{1-4} alkyl substituents ;

Het⁴ represents tetrazolyl;

Het⁵ represents morpholinyl;

Het⁶ represents a monocyclic heterocycle selected from pyrrolidinyl, piperazinyl or morpholinyl, said Het⁶ optionally being substituted with one or where possible two or more hydroxy substituents, preferably with one hydroxy substituent;

Ar² represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, benzocyclobutene, benzocycloheptanyl, benzosuberonyl, indenyl, 2,3-dihydroindenyl, 5,6,7,8-tetrahydronaphthyl or naphthyl.


5. (Previously Presented) A compound according to claim 1 wherein;

R^1 and R^2 each independently represents hydrogen C_{1-4} alkyl, NR^9R^{10} ; or

R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6} cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated bond;

R^3 represents a C_{6-12} cycloalkyl or a monovalent radical having one of the following formulae

PRD 2023USPCT



wherein said C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, halo, carbonyl, hydroxy, or 1,3-dioxolyl;
 Q represents Het¹ or Ar² wherein said Het¹ or Ar² are optionally substituted with one or where possible two or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, C_{1-4} alkyloxycarbonyl, Het⁴, NR⁵R⁶, C_{1-4} alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het² and NR⁷R⁸, C_{2-4} alkenyl substituted with one substituent selected from phenyl- C_{1-4} alkyloxycarbonyl or Het⁵-carbonyl and C_{1-4} alkyl substituted with one or where possible two or three substituents each independently selected from halo, dimethylamine, amine, cyano, Het⁶, Het⁷-carbonyl or hydroxycarbonyl;
 R⁵ and R⁶ are each independently selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkylcarbonyl, C_{1-4} alkylcarbonyl substituted with one or where possible two or three halo substituents.
 R⁹ and R¹⁰ are each independently selected from hydrogen or C_{1-4} alkyl;
 L represents a C_{1-4} alkyl, preferably methyl;
 Het¹ represents a heterocycle selected from pyridinyl, pyrimidinyl, indolyl, thiophenyl, benzothiophenyl, quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, 2H-benzopyranyl,

PRD 2023USPCT

3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;

Het² represents a monocyclic heterocycle selected from piperidinyl, piperazinyl, pyridinyl, pyrrolidinyl or morpholinyl, said Het² optionally being substituted with one or where possible two or more C₁₋₄alkyl substituents ;

Het⁴ represents tetrazolyl;

Het⁵ represents morpholinyl;

Het⁶ represents a monocyclic heterocycle selected from pyrrolidinyl, piperazinyl or morpholinyl, said Het⁶ optionally being substituted with one or where possible two or more hydroxy substituents, preferably with one hydroxy substituent;

Het⁷ represents a monocyclic heterocycle selected from piperazinyl or morpholinyl, preferably morpholinyl;

Ar² represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, benzocyclobutene, benzocycloheptanyl, benzosubereryl, indenyl, 2,3-dihydroindenyl, 5,6,7,8-tetrahydronaphthyl or naphthyl.

6. (Previously Presented) A compound according to claim 1 wherein;


n represents an integer being 0, 1 or 2;

R¹ and R² each independently represents hydrogen, C₁₋₄alkyl, NR⁹R¹⁰; or

R¹ and R² taken together with the carbon atom with which they are attached form a C₃₋₆cycloalkyl; and where n is 2, either R¹ or R² may be absent to form an unsaturated bond;

R³ represents a C₆₋₁₂cycloalkyl, preferably cylo-octanyl or a monovalent radical having one of the following formulae

PRD 2023USPCT



, preferably having the formula (a) or (b) above, wherein said C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, halo or hydroxy;

Q represents Het^1 or Ar^2 wherein said Het^1 or Ar^2 are optionally substituted with one or where possible two or more substituents selected from

halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, NR^5R^6 ,

C_{1-4} alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het^2 or NR^7R^8 ,

C_{2-4} alkenyl substituted with one substituent selected from phenyl- C_{1-4} alkyloxycarbonyl or Het^5 -carbonyl

and C_{1-4} alkyl substituted with one or where possible two or three substituents selected from halo, Het^6 , C_{1-4} alkyloxycarbonyl or hydroxycarbonyl;

R^5 and R^6 each independently represent hydrogen or C_{1-4} alkyl;

R^9 and R^{10} each independently represent hydrogen or C_{1-4} alkyloxycarbonyl;

L represents C_{1-4} alkyl;

Het^1 represents a heterocycle selected from pyridinyl, piperidinyl, thiophenyl, 1,2,3,4-tetrahydro-quinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxol;


Het^2 represents pyridinyl, pyrrolidinyl or morpholinyl;

Het^6 represents morpholinyl;

PRD 2023USPCT

Ar² represents phenyl, benzocyclobutene, benzocycloheptanyl, benzosuberonyl, 2,3-dihydroindenyl, 5,6,7,8-tetrahydronaphthyl, naphthyl or indenyl.

7. (Original) A compound as claimed in claim 1 wherein
- n represents an integer being 0, 1 or 2;
- (R¹ and R² each independently represents hydrogen C₁₋₄alkyl, NR⁹R¹⁰, C₁₋₄alkyloxy; or R¹ and R² taken together with the carbon atom with which they are attached form a C₃₋₆cycloalkyl; and where n is 2, either R¹ or R² may be absent to form an unsaturated bond;
- R³ represents a C₆₋₁₂cycloalkyl, preferably selected from cylo-octanyl and cyclohexyl or R³ represents a monovalent radical having one of the following formulae



, preferably having the formula (a) above, wherein said C₆₋₁₂cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyloxy, halo or hydroxy;

R⁴ represents hydrogen or C₁₋₄alkyl;

Q represents Het¹ or Ar² wherein said C₃₋₈cycloalkyl, Het¹ or Ar² are optionally substituted with one or where possible two or more substituents selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, nitro, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het² or NR⁷R⁸, C₂₋₄alkenyl substituted with phenyl-C₁₋₄alkyl-oxycarbonyl and C₁₋₄alkyl substituted with one or where possible two or three substituents selected from, halo, Het⁶, Het⁷-carbonyl, C₁₋₄alkyloxycarbonyl or hydroxycarbonyl;

PRD 2023USPCT
R⁵ and R⁶ each independently represent hydrogen, C₁₋₄alkyl, or C₁₋₄alkyl substituted with phenyl;

L represents C₁₋₄alkyl;

Het¹ represents a heterocycle selected from pyridinyl, thiophenyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;

Het² represents piperidinyl, pyrrolidinyl or morpholinyl;

Het⁶ represents a monocyclic heterocycle selected from piperazinyl or morpholinyl, preferably morpholinyl;

Ar² represents phenyl, benzocyclobutene, benzocycloheptanyl, benzosubereryl, 2,3-dihydroindenyl, 1,2-dihydronaphthyl, 5,6,7,8-tetrahydronaphthyl, naphthyl or indenyl.

8. (Original) A compound as claimed in claim 1 wherein the compound is
- (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;
 - (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-methyl-benzeneacetamide;
 - (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-methoxy-benzeneacetamide;
 - (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-hydroxy-benzeneacetamide;
 - (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3,5-dimethyl-benzeneacetamide);
 - (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)-3-(phenylmethoxy)benzeneacetamide;
 - (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-(carboxymethoxy)-benzeneacetamide;
 - (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-[2-(4-morpholinyl)ethoxy]-benzeneacetamide;

PRD 2023USPCT

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-fluorotricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-methoxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;

(1 α ,2 α ,3 β ,5 β ,7 β)-N-(5-methoxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-(carboxymethoxy)-benzeneacetamide;

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-[2-(4-morpholinyl)ethoxy]-benzeneacetamide;

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3,5-dimethoxy-benzeneacetamide;

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-methyl-benzeneacetamide;

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-methoxy-benzeneacetamide;

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-hydroxy-benzeneacetamide;

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3,5-dimethyl-benzeneacetamide;

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-4-fluoro-benzeneacetamide;

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)-1-phenyl-cyclopropanecarboxamide;

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-2,6-difluoro-benzeneacetamide;

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-2-thiopheneacetamide;

N-(5-hydroxy-2-adamantyl)-2-methyl-2-(5-methylpyridin-3-yl)propanamide;

N-(5-hydroxy-2-adamantyl)-2-methyl-2-(6-methylpyridin-2-yl)propanamide;

3-(3-{2-[(5-fluoro-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)propanoic acid;

4-(3-{2-[(5-hydroxy-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)butanoic acid;

tert-butyl-4-[3-(3-{2-[(5-hydroxy-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)propanoyl]-1,4-diazepane-1-carboxylate;


N-(5-hydroxy-2-adamantyl)-5-methoxy-1,2,3,4-tetrahydronaphthalene-1-carboxamide;

N-2-adamantyl-1,2,3,4-tetrahydroisoquinoline-1-carboxamide;

PRD 2023USPCT

N-(5-hydroxy-2-adamantyl)-3,4-dihydroquinoline-1(2*H*)-carboxamide;
or a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.

9. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, an effective $\alpha\beta$ -HSD1 inhibitory amount of a compound of claim 1.
10. (Previously Presented) A process of preparing a pharmaceutical composition as defined in claim 9, characterized in that, a pharmaceutically acceptable carrier is intimately mixed with an effective $\alpha\beta$ -HSD1 inhibitory amount of a compound of claim 1.
11. (Cancelled)
12. (Previously Presented) A method of treating pathologies associated with excess cortisol formation selected from the group consisting of obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis and glaucoma comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.
13. (Currently Amended) A compound of formula (I')



the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof wherein

R^1 and R^2 each independently represents hydrogen, C_{1-4} alkyl, NR^9R^{10} , C_{1-4} alkyloxy or Het^3 - O - C_{1-4} alkyl; preferably C_{1-4} alkyl in particular methyl; or

PRD 2023USPCT

R¹ and R² taken together with the carbon atom with which they are attached from a

C₃₋₆cycloalkyl, in particular cyclopropyl or cyclobutyl;

R⁴ represents hydrogen, C₁₋₄alkyl, or C₂₋₄alkenyl;

U represents hydrogen, C₁₋₄alkyl, C₁₋₄alkyloxy, phenyl, halo, oxo, carbonyl or hydroxyl;

R⁵ and R⁶ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyl substituted with one or where possible two or three substituents each independently selected from halo, C₁₋₄alkyl, and C₁₋₄alkyloxy or R⁵ and R⁶ each independently represent C₁₋₄alkyl substituted with phenyl;

R⁷ and R⁸ are each independently selected from hydrogen or C₁₋₄alkyl;

R⁹ and R¹⁰ are each independently selected from hydrogen, C₁₋₄alkyl or C₁₋₄alkyloxycarbonyl;

R¹¹ and R¹² are each independently selected from hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, nitro, Het⁴, phenyl, phenyloxy, C₁₋₄alkyloxycarbonyl, hydroxycarbonyl, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het² and NR⁷R⁸, C₂₋₄alkenyl substituted with one substituent selected from phenyl-C₁₋₄alkyl-oxycarbonyl, C₁₋₄alkyloxycarbonyl, hydroxycarbonyl, Het⁵-carbonyl, and C₁₋₄alkyl substituted with one or where possible two or three substituents independently selected from halo, dimethylamine, trimethylamine, amine, cyano, Het⁶, Het⁷-carbonyl, C₁₋₄alkyloxycarbonyl or hydroxycarbonyl;


Het¹ represents a heterocycle selected from pyridinyl, piperidinyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, furanyl, benzofuranyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, benzothiophenyl, thiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl.;

Het² represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl, said Het² optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy;;

PRD 2023USPCT

- Het³ represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;
- Het⁴ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl, triazolyl, tetrazolyl or morpholinyl, said Het⁴ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy;
- Het⁵ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁵ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy; preferably piperazinyl or morpholinyl;
- Het⁶ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁶ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy;
- Het⁷ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁷ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy; preferably piperazinyl or morpholinyl; in particular morpholinyl.

14. (Original) A compound of formula (I')



the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

R⁴ represents hydrogen, C₁₋₄alkyl, C₂₋₄alkenyl;

U represents hydrogen, C₁₋₄alkyl, C₁₋₄alkyloxy, phenyl, halo, oxo, carbonyl or hydroxy


PRD 2023USPCT

- Q represents Het¹ or Ar², wherein said Het¹ or Ar² are optionally substituted with one or where possible more substituents selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, nitro, Het⁴, phenyl, phenyloxy, C₁₋₄alkyloxycarbonyl, hydroxycarbonyl, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het² and NR⁷R⁸, and C₁₋₄alkyl substituted with one or where possible two or three substituents independently selected from halo or hydroxycarbonyl;
- R⁵ and R⁶ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyl substituted with one or where possible two or three substituents each independently selected from halo, C₁₋₄alkyl, and C₁₋₄alkyloxy or R⁵ and R⁶ each independently represent C₁₋₄alkyl substituted with phenyl;
- R⁷ and R⁸ are each independently selected from hydrogen or C₁₋₄alkyl;
- R⁹ and R¹⁰ are each independently selected from hydrogen, C₁₋₄alkyl or C₁₋₄alkyloxycarbonyl;
- Het¹ represents a bicyclic heterocycle selected from indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;
- Het² represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl, said Het² optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, C₁₋₄alkyl or C₁₋₄alkyloxy;
- Het³ represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;
- Het⁴ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁴ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy;

PRD 2023USPCT

Ar² represents carbocyclic radicals containing two rings selected from the group consisting of benzocyclobutene, benzocycloheptanyl, benzosuberonyl, indenyl, 2,3-dihydroindenyl, 5,6,7,8-tetrahydronaphthyl or naphthyl.

15. (Cancelled)
16. (Previously Presented) A method of treating pathologies associated with excess cortisol formation selected from the group consisting of obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis and glaucoma comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 13.
17. (Previously Presented) A method to prepare 1-hydroxy-4-aminoadamantane said method comprising
- i) reductively aminating a corresponding ketone (XIII) to obtain stereoisomers of an amine of formula (XVIII);
 - ii) separating the thus obtained stereoisomers of the amine of formula (XVIII); and
 - iii) debenzylating the compounds of formula (XVIII)




18. (Previously Presented) A compound according to claim 2 wherein;

PRD 2023USPCT

n represents an integer being 1 or 2 provided that when n represents 2, Q represents Het¹ or Ar², wherein said Het¹ or Ar² are optionally substituted with one or where possible more substituents selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, nitro, Het⁴, phenyl, phenyloxy, hydroxycarbonyl, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het² and NR⁷R⁸, and

19. (Previously Presented) A compound according to claim 2 wherein:
 R¹ and R² each independently represents hydrogen C₁₋₄alkyl, NR⁹R¹⁰; or
 R¹ and R² taken together with the carbon atom with which they are attached form a C₃cycloalkyl; and where n is 2, either R¹ or R² may be absent to form an unsaturated bond;
 R³ represents a C₆₋₁₂cycloalkyl or a monovalent radical having one of the following formulae



wherein said C₆₋₁₂cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkyloxy, halo, carbonyl, hydroxy, or 1,3-dioxolyl;
 Q represents Het¹ or Ar² wherein said Het¹ or Ar² are optionally substituted with one or where possible two or more substituents selected from halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, C₁₋₄alkyloxycarbonyl, Het⁴, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible two or three substituents each

PRD 2023USPCT

independently selected from hydroxycarbonyl, Het² and NR⁷R⁸,

C₂₋₄alkenyl substituted with one substituent selected from phenyl-C₁₋₄alkyl-oxycarbonyl or Het⁵-carbonyl and

C₁₋₄alkyl substituted with one or where possible two or three substituents each independently selected from halo, dimethylamine, amine, cyano, Het⁶, Het⁷-carbonyl or hydroxycarbonyl;

R⁵ and R⁶ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyl substituted with one or where possible two or three halo substituents.

R⁹ and R¹⁰ are each independently selected from hydrogen or C₁₋₄alkyl;

L represents a C₁₋₄alkyl, preferably methyl;

Het¹ represents a heterocycle selected from pyridinyl, pyrimidinyl, indolyl, thiophenyl, benzothiophenyl, quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;

Het² represents a monocyclic heterocycle selected from piperidinyl, piperazinyl, pyridinyl, pyrrolidinyl or morpholinyl, said Het² optionally being substituted with one or where possible two or more C₁₋₄alkyl substituents ;

Het⁴ represents tetrazolyl;

Het⁵ represents morpholinyl;

Het⁶ represents a monocyclic heterocycle selected from pyrrolidinyl, piperazinyl or morpholinyl, said Het⁶ optionally being substituted with one or where possible two or more hydroxy substituents, preferably with one hydroxy substituent;

Het⁷ represents a monocyclic heterocycle selected from piperazinyl or morpholinyl, preferably morpholinyl;

Ar² represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, benzocyclobutene, benzocycloheptanyl, benzosubereryl, indenyl, 2,3-dihydroindenyl, 5,6,7,8-tetrahydronaphthyl or naphthyl.


20. (Previously Presented) A compound according to claim 3 wherein;

R¹ and R² each independently represents hydrogen C₁₋₄alkyl, NR⁹R¹⁰; or

PRD 2023USPCT

R^1 and R^2 taken together with the carbon atom with which they are attached form a C_3 -cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated bond;

R^3 represents a C_{6-12} cycloalkyl or a monovalent radical having one of the following formulae



wherein said C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, halo, carbonyl, hydroxy, or 1,3-dioxolyl;

Q represents Het^1 or Ar^2 wherein said Het^1 or Ar^2 are optionally substituted with one or where possible two or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, C_{1-4} alkyloxycarbonyl, Het^4 , NR^5R^6 , C_{1-4} alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8 , C_{2-4} alkenyl substituted with one substituent selected from phenyl- C_{1-4} alkyloxycarbonyl or Het^5 -carbonyl and C_{1-4} alkyl substituted with one or where possible two or three substituents each independently selected from halo, dimethylamine, amine, cyano, Het^6 , Het^7 -carbonyl or hydroxycarbonyl;

R^5 and R^6 are each independently selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkylcarbonyl, C_{1-4} alkylcarbonyl substituted with one or where possible two or three halo substituents,

PRD 2023USPCT

R⁹ and R¹⁰ are each independently selected from hydrogen or C₁₋₄alkyl;

L represents a C₁₋₄alkyl, preferably methyl;

Het¹ represents a heterocycle selected from pyridinyl, pyrimidinyl, indolyl, thiophenyl, benzothiophenyl, quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;

Het² represents a monocyclic heterocycle selected from piperidinyl, piperazinyl, pyridinyl, pyrrolidinyl or morpholinyl, said Het² optionally being substituted with one or where possible two or more C₁₋₄alkyl substituents ;

Het⁴ represents tetrazolyl;

Het⁵ represents morpholinyl;

Het⁶ represents a monocyclic heterocycle selected from pyrrolidinyl, piperazinyl or morpholinyl, said Het⁶ optionally being substituted with one or where possible two or more hydroxy substituents, preferably with one hydroxy substituent;

Het⁷ represents a monocyclic heterocycle selected from piperazinyl or morpholinyl, preferably morpholinyl;

Ar² represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, benzocyclobutene, benzocycloheptanyl, benzosubereryl, indenyl, 2,3-dihydroindenyl, 5,6,7,8-tetrahydronaphthyl or naphthyl.

21. (Previously Presented) A compound according to claim 2 wherein;


n represents an integer being 0, 1 or 2;

R¹ and R² each independently represents hydrogen, C₁₋₄alkyl, NR⁹R¹⁰; or

R¹ and R² taken together with the carbon atom with which they are attached form a C₃₋₆cycloalkyl; and where n is 2, either R¹ or R² may be absent to form an unsaturated bond;

R³ represents a C₆₋₁₂cycloalkyl, preferably cyclo-octanyl or a monovalent radical having one of the following formulae

PRD 2023USPCT



, preferably having the formula (a) or (b) above, wherein said C_{6-12} cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkyloxy, halo or hydroxy;

Q represents Het^1 or Ar^2 wherein said Het^1 or Ar^2 are optionally substituted with one or where possible two or more substituents selected from halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, NR^5R^6 ,

C_{1-4} alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het^2 or NR^7R^8 , C_{2-4} alkenyl substituted with one substituent selected from phenyl- C_{1-4} alkyloxycarbonyl or Het^5 -carbonyl

and C_{1-4} alkyl substituted with one or where possible two or three substituents selected from halo, Het^6 , C_{1-4} alkyloxycarbonyl or hydroxycarbonyl;

R^5 and R^6 each independently represent hydrogen or C_{1-4} alkyl;

R^9 and R^{10} each independently represent hydrogen or C_{1-4} alkyloxycarbonyl;

L represents C_{1-4} alkyl;

Het^1 represents a heterocycle selected from pyridinyl, piperidinyl, thiophenyl, 1,2,3,4-tetrahydro-quinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxol;

Het^2 represents pyridinyl, pyrrolidinyl or morpholinyl;

Het^6 represents morpholinyl;

PRD 2023USPCT

Ar² represents phenyl, benzocyclobutene, benzocycloheptanyl, benzosuberonyl, 2,3-dihydroindenyl, 5,6,7,8-tetrahydronaphthyl, naphthyl or indenyl.

22. (Previously Presented) A method of treating pathologies associated with excess cortisol formation selected from the group consisting of obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis and glaucoma comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 14.
23. (New) A compound according to claim 13, wherein R¹ and R² each independently represents hydrogen, C₁₋₄alkyl, or C₁₋₄alkoxy.
24. (New) A compound according to claim 13, wherein R¹ and R² each independently represents methyl or methoxy.
25. (New) A compound according to claim 13, wherein R¹ and R² taken together with the carbon atom with which they are attached form cyclopropyl or cyclobutyl.
26. (New) A compound according to claim 13, wherein R⁴ represents hydrogen.
27. (New) A compound according to claim 13, wherein U represents hydrogen, hydroxy or halo.
28. (New) A compound according to claim 13, wherein Het⁵ represents a monocyclic heterocycle selected from piperazinyl or morpholinyl;
29. (New) A compound according to claim 13, wherein Het⁷ represents a monocyclic heterocycle selected from preferably piperazinyl or morpholinyl.
30. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, an effective 11 β -HSD1 inhibitory amount of a compound of claim 13.

PRD 2023USPCT

31. (New) A process of preparing a pharmaceutical composition as defined in claim 31, wherein a pharmaceutically acceptable carrier is intimately mixed with an effective 11β -HSD1 inhibitory amount of a compound of claim 13.

32. (New) A compound according to claim 13, wherein the compound is:

- (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-benzeneacetamide;
- (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3-methyl-benzeneacetamide;
- (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3-methoxy-benzeneacetamide;
- (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3-hydroxy-benzeneacetamide;
- (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3,5-dimethyl-benzeneacetamide;
- (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)-3-(phenylmethoxy)benzeneacetamide;
- (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3-(carboxymethoxy)-benzeneacetamide;
- (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3-[2-(4-morpholinyl)ethoxy]-benzeneacetamide;
- (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-fluorotricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-benzeneacetamide;
- (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-methoxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-benzeneacetamide;
- (1 α ,2 α ,3 β ,5 β ,7 β)-N-(5-methoxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-benzeneacetamide;
- N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-benzeneacetamide;
- N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3-(carboxymethoxy)-benzeneacetamide;
- N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3-[2-(4-morpholinyl)ethoxy]-benzeneacetamide;
- N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3,5-dimethoxy-benzeneacetamide;
- N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3-methyl-benzeneacetamide;

PRD 2023USPCT

N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3-methoxy-benzeneacetamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3-hydroxy-benzeneacetamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-3,5-dimethyl-benzeneacetamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-4-fluoro-benzeneacetamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)-1-phenyl-cyclopropanecarboxamide;
N-(tricyclo[3.3.1.1^{3,7}]dec-2-yl)- α,α -dimethyl-2,6-difluoro-benzeneacetamide;
3-(3-{2-[(5-fluoro-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)propanoic acid;
4-(3-{2-[(5-hydroxy-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)butanoic acid; and
tert-butyl-4-[3-(3-{2-[(5-hydroxy-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)propanoyl]-1,4-diazepane-1-carboxylate; or a N-oxide, a pharmaceutically acceptable addition salt, or a stereochemically isomeric form thereof.